A phase 1b study of the anti-PD-1 monoclonal antibody BGB-A317 (A317) in combination with the PARP inhibitor BGB-290 (290) in advanced solid tumors.

Michael Friedlander; Tarek Meniawy; Ben Markman; Linda R. Mileshkin; Paul R. Harnett; Michael Millward; Joanne Lundy; Alison E. Freimund; Christie Norris; Song Mu; John Wu; Virginia E. Paton; Lai Wang; Bo Gao

doi:10.1200/JCO.2017.35.15_suppl.3013

A phase 1b study of the anti-PD-1 monoclonal antibody BGB-A317 (A317) in combination with the PARP inhibitor BGB-290 (290) in advanced solid tumors.

Michael Friedlander, Tarek Meniawy, Ben Markman, Linda R. Mileshkin, Paul R. Harnett, Michael Millward, Joanne Lundy, Alison E. Freimund, Christie Norris, Song Mu, John Wu, Virginia E. Paton, Lai Wang, Bo Gao

UWA Medical School

Research output: Contribution to journal › Abstract/Meeting Abstract › peer-review

16 Citations (Web of Science)

Original language	English
Number of pages	5
Journal	Journal of Clinical Oncology
Volume	35
DOIs	https://doi.org/10.1200/JCO.2017.35.15_suppl.3013
Publication status	Published - 20 May 2017
Event	53rd Annual Clinical Meeting of the American-Society-of-Clinical-Oncology (ASCO) - Chicago, United States Duration: 2 Jun 2017 → 7 Jun 2017 https://www.bcrf.org/blog/53rd-annual-meeting-american-society-clinical-oncology-kicks-call-action/

Access to Document

10.1200/JCO.2017.35.15_suppl.3013

Cite this

Friedlander, M., Meniawy, T., Markman, B., Mileshkin, L. R., Harnett, P. R., Millward, M., Lundy, J., Freimund, A. E., Norris, C., Mu, S., Wu, J., Paton, V. E., Wang, L., & Gao, B. (2017). A phase 1b study of the anti-PD-1 monoclonal antibody BGB-A317 (A317) in combination with the PARP inhibitor BGB-290 (290) in advanced solid tumors. Journal of Clinical Oncology, 35. https://doi.org/10.1200/JCO.2017.35.15_suppl.3013

@article{16be70579575471095bc1a2f4f7c382f,

title = "A phase 1b study of the anti-PD-1 monoclonal antibody BGB-A317 (A317) in combination with the PARP inhibitor BGB-290 (290) in advanced solid tumors.",

author = "Michael Friedlander and Tarek Meniawy and Ben Markman and Mileshkin, {Linda R.} and Harnett, {Paul R.} and Michael Millward and Joanne Lundy and Freimund, {Alison E.} and Christie Norris and Song Mu and John Wu and Paton, {Virginia E.} and Lai Wang and Bo Gao",

year = "2017",

month = may,

day = "20",

doi = "10.1200/JCO.2017.35.15_suppl.3013",

language = "English",

volume = "35",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "American Society of Clinical Oncology",

note = "53rd Annual Clinical Meeting of the American-Society-of-Clinical-Oncology (ASCO), ASCO ; Conference date: 02-06-2017 Through 07-06-2017",

url = "https://www.bcrf.org/blog/53rd-annual-meeting-american-society-clinical-oncology-kicks-call-action/",

}

Friedlander, M, Meniawy, T, Markman, B, Mileshkin, LR, Harnett, PR, Millward, M, Lundy, J, Freimund, AE, Norris, C, Mu, S, Wu, J, Paton, VE, Wang, L & Gao, B 2017, 'A phase 1b study of the anti-PD-1 monoclonal antibody BGB-A317 (A317) in combination with the PARP inhibitor BGB-290 (290) in advanced solid tumors.', Journal of Clinical Oncology, vol. 35. https://doi.org/10.1200/JCO.2017.35.15_suppl.3013

TY - JOUR

T1 - A phase 1b study of the anti-PD-1 monoclonal antibody BGB-A317 (A317) in combination with the PARP inhibitor BGB-290 (290) in advanced solid tumors.

AU - Friedlander, Michael

AU - Meniawy, Tarek

AU - Markman, Ben

AU - Mileshkin, Linda R.

AU - Harnett, Paul R.

AU - Millward, Michael

AU - Lundy, Joanne

AU - Freimund, Alison E.

AU - Norris, Christie

AU - Mu, Song

AU - Wu, John

AU - Paton, Virginia E.

AU - Wang, Lai

AU - Gao, Bo

PY - 2017/5/20

Y1 - 2017/5/20

U2 - 10.1200/JCO.2017.35.15_suppl.3013

DO - 10.1200/JCO.2017.35.15_suppl.3013

M3 - Abstract/Meeting Abstract

SN - 0732-183X

VL - 35

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

T2 - 53rd Annual Clinical Meeting of the American-Society-of-Clinical-Oncology (ASCO)

Y2 - 2 June 2017 through 7 June 2017

ER -